Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-254623
Filing Date
2026-06-03
Accepted
2026-06-03 08:00:55
Documents
84
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ck0001540171-20260331.htm   iXBRL 10-Q 2683443
2 EX-10.9 ck0001540171-ex10_9.htm EX-10.9 77286
3 EX-10.10 ck0001540171-ex10_10.htm EX-10.10 75933
4 EX-10.11 ck0001540171-ex10_11.htm EX-10.11 76270
5 EX-10.12 ck0001540171-ex10_12.htm EX-10.12 76620
6 EX-31.1 ck0001540171-ex31_1.htm EX-31.1 17560
7 EX-31.2 ck0001540171-ex31_2.htm EX-31.2 17299
8 EX-32.1 ck0001540171-ex32_1.htm EX-32.1 9830
9 EX-32.2 ck0001540171-ex32_2.htm EX-32.2 9852
  Complete submission text file 0001193125-26-254623.txt   9922455

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001540171-20260331.xsd EX-101.SCH 1023846
88 EXTRACTED XBRL INSTANCE DOCUMENT ck0001540171-20260331_htm.xml XML 1710564
Mailing Address 105 W FIRST ST. BOSTON MA 02127
Business Address 105 W FIRST ST. BOSTON MA 02127 (206) 707-0340
Avalyn Pharma Inc. (Filer) CIK: 0001540171 (see all company filings)

EIN.: 452463191 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43251 | Film No.: 261058956
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)